NexMed Announces Encouraging Pre-Clinical Results Showing the Ability of the NexACT(R) Technology to Enhance the Bioavailability of rituximab When Administered Subcutaneously

SAN DIEGO--(BUSINESS WIRE)--NexMed, Inc. (NASDAQ: NEXM), a specialty CRO with a pipeline of products based on the NexACT® technology, today announced data from a pre-clinical study examining the subcutaneous delivery of rituximab, the first FDA-approved therapeutic antibody for the treatment of cancer in the United States. The study results showed that animals receiving subcutaneous injections of rituximab, incorporated with NexACT, demonstrated a 46% enhancement in bioavailability over rituximab, alone.